Halozyme Therapeutics News and Activities

Presence

Halozyme Therapeutics develops and commercializes drug delivery technologies and biotechnology therapies. Its products and services support pharmaceutical partners, healthcare providers, and patients in oncology, immunology, and other treatment areas.

Halozyme Therapeutics products and services overview:

Drug delivery technology
Biologic therapies
Injection solutions
Licensing services
Pharmaceutical partnerships

Revenue: ~$1 billion

Employees: 450

Headquarters: San Diego, United States (USA)

Halozyme Therapeutics is one of the...

Halozyme Therapeutics is a company listed under the stock ticker HALO (US).

Acquisition, funding and merger involving Halozyme Therapeutics.

Halozyme Therapeutics has announced the acquisition of Elektrofi (posted on October 2 2025).

Executives

View the org chart displaying its 32 main executives

Most searched biographies at Halozyme Therapeutics

Popular executive movements at Halozyme Therapeutics

Darren Snellgrove will join the company as Chief Financial Officer on Jun. 8, 2026 (posted on April 30 2026).
David Ramsay will join the company as Interim Chief Financial Officer on Mar. 23, 2026 (posted on March 13 2026).
Jim Lang has joined the company as Director (posted on December 10 2025).

Click here to view some more movements at Halozyme Therapeutics

Create your alert
to follow the executive moves at Halozyme Therapeutics.